-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

Benzinga·11/10/2026 14:27:02
Listen to the news
BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $2 price target.